


L1 STRUCTURE UPLOADED

=&gt; d 11

L1 HAS NO ANSWERS

L1 STR



G1 Me,Et,n-Pr,n-Bu,H

Structure attributes must be viewed using STN Express query preparation.

=&gt; s 11

SAMPLE SEARCH INITIATED 16:25:04 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 16 TO ITERATE

100.0% PROCESSED 16 ITERATIONS 0 ANSWERS  
SEARCH TIME: 00.00.01FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 80 TO 560

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s 11 sss full  
FULL SEARCH INITIATED 16:25:13 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 345 TO ITERATE100.0% PROCESSED 345 ITERATIONS 51 ANSWERS  
SEARCH TIME: 00.00.02

L3 51 SEA SSS FUL L1

=> file caplus  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
FULL ESTIMATED COST ENTRY SESSION  
185.88 186.10

FILE 'CAPLUS' ENTERED AT 16:25:18 ON 07 MAY 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 May 2009 VOL 150 ISS 19  
FILE LAST UPDATED: 6 May 2009 (20090506/ED)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2009  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2009

CAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:


<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate

```
=> s 13
L4          4 L3
=> d ibib abs hitstr tot
```

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 20071933627 CAPLUS  
DOCUMENT NUMBER: 146274087  
TITLE: Preparation of  $\alpha$ -thioesters and  
benzenesulfonates as their intermediates  
INVENTOR(S): Fujiiwa, Yuji; Takahashi, Kazuhiko  
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan; Dainippon  
Pharmaceutical Co., Ltd.  
SOURCE: Jpn. Kokai Tokkyo Koho, 20pp.  
CODEN: JKXXAF  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:  
PATENT NO. KIND DATE APPLICATION NO. DATE

OTHER SOURCE(S): MARPAT 146:274087  
GT




AB (optically active)  $\alpha$ -thioesters I [R1 = H, halo, alkoxy; R2 = alkyl; R4 = H, alkyl(oxy), aryl(oxy), alkoxy carbonyl, cyano], useful as intermediates for benzothiazin-3-ones as matrix metalloprotease inhibitors, are prepared by treatment of (optically active) benzenesulfonates II [R1, R2 = same as above; R3 = H, alkyl(oxy), aryl(oxy), halo, NO<sub>2</sub>, cyano, alkoxy carbonyl] with 2-nitrothiophenols (R4 = same as above) under basic conditions. Thus, Me (R)-2-hydroxy-5-(4-methoxyphenyl)pentanoate (97.5% ee) was tosylated and treated with Et 4-mercaptopro-3-nitrobenzoate and N-methylmorpholine to give the corresponding  $\alpha$ -thioester (97.0% ee) with 69.1% yield.  
 IT 864162-60-7  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of  $\alpha$ -thioesters as intermediates for benzothiazinones as matrix metalloprotease inhibitors via benzenesulfonates)  
 PN 864162-60-7. CAPLUS

14 ANSWER 2 OF 4 CAPLUS PREPARATION 2009 ACS on STN  
ACCESSION NUMBER: 20051979628 CAPLUS  
DOCUMENT NUMBER: 143-286436  
TITLE: Preparation of 1,4-benzothiazine-3-one derivatives as  
MMP-13 inhibitors  
INVENTOR(S): Samizo, Fumio; Horiochi, Yoshihiro; Fukuda, Nobuhisa;  
Tsuboi, Katsunori; Makita, Atsushi  
PATENT ASSIGNEE(S): Sumitomo Pharmaceuticals Co., Ltd., Japan  
SOURCE: PCT Int. Appl., 94 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


| PATENT NO.   | KIND | DATE  | APPLICATION NO. | DATE       |
|--|------|---|-----------------|------------|
| WO 2005082872  | A1   | 20050909  | WO 2005-JP3821  | 20050228   |
| W: AI, AG, AL, AM, AT, AU, AZ, CN, CO, CR, CU, CZ, DE, DK, GH, GM, HE, HO, ID, IL, LK, LS, LT, LU, LV, MA, NO, NZ, OM, PG, PL, PT, SV, TJ, TM, TN, TR, TT, TZ,   | AI   | BA, BB, BG, BR, BW, BY, BZ, CA, CH, CR, DE, DZ, EE, EG, ES, FI, GB, GD, GE, HE, HS, KE, KG, KP, KR, LC, MD, MG, MK, MN, MW, MX, NA, NI, RO, RU, SD, SE, SG, SK, SL, SM, SU, TC, VE, VN, YU, ZA, ZM, |                 |            |
| ZW   |      |   |                 |            |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GR, HK, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG |      |   |                 |            |
| CA 2560664   | A1   | 20050909  | CA 2005-2560664 | 20050228   |
| EP 1726587   | A1   | 20061129  | EP 2005-720093  | 20050228   |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GR, GB, GR, HO, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR  |      |   |                 |            |
| US 20080058321   | A1   | 20080306  | US 2007-598516  | 20070618   |
| PRIORITY APPLN. INFO.:   |      |   | JP 2004-578081  | A 20040302 |
|  |      |   | WO 2005-JP3821  | W 20050228 |

OTHER SOURCE(S): MARPAT 143:286436  
GI

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
CN 2H-1, 4-Benzothiazine-6-carboxylic acid,  
  
3,4-dihydro-4-[2-(hydroxymino)-2-oxoethyl]-2-[3-(4-methoxyphenyl)propyl]-  
3-oxo-, ethyl ester, (2S)- (CA INDEX NAME)  
  
Absolute stereochemistry. Rotation (-).




L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



AB Title compds. represented by the formula I [wherein R = H or Et; R1 = halo(alkyl), (halo)alkoxy, n = 3 or 4; and pharmaceutically acceptable salts thereof] were prepared as matrix metalloprotease 13 (MMP-13) inhibitors. For example, II was given in a multi-step synthesis starting from the reaction of anisole with succinic acid anhydride. II showed inhibition of MMP-13 with an IC50 value of 440 nM and cartilage degeneration with 50% inhibition rate at 50 mg/Kg. Thus, I and their pharmaceutical compns. are useful as MMP inhibitors for the treatment or prevention of cartilage degeneration and inflammations.

IT 864162-54-9P 864162-60-7P  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of 1,4-benzothiazine-3-one derivs. as MMP-13 inhibitors  
RN 864162-54-9 CAPLUS  
2H-1,4-Benzothiazine-6-carboxylic acid.


3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-2-[3-(4-methoxyphenyl)propyl]-3-oxo-ethyl ester (CA INDEX NAME)



RN 864162-60-7 CAPLUS  
CN 2H-1,4-Benzothiazine-6-carboxylic acid

3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-2-[3-(4-methoxyphenyl)propyl]-3-oxo-, ethyl ester, (2S)- (CA INDEX NAME)


### Absolute stereochemistry. Rotation (-).



IT 864162-55-0P 864162-56-1P 864162-57-2P  
 864162-58-3P 864162-59-4P 864162-61-8P  
 864162-62-9P 864162-63-0P 864162-64-1P  
 864162-65-2P 864162-66-3P 864162-67-4P  
 864162-76-5P 864162-91-4P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (preparation of 1,4-benzothiazine-3-one derivs. as MMP-13 inhibitors)


RN 864162-55-0 CAPLUS  
 CN 2H-1, 4-Benzothiazine-6-carboxylic acid,

2-[3-(4-chlorophenyl)propyl]-3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo-, ethyl ester (CA INDEX NAME)




RN 864162-56-1 CAPLUS  
 CN 2H-1, 4-Benzothiazine-6-carboxylic acid,


2-[3-(4-fluorophenyl)propyl]-3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo-, ethyl ester (CA INDEX NAME)




RN 864162-61-8 CAPLUS  
 CN 2H-1, 4-Benzothiazine-6-carboxylic acid,  
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-2-[3-(4-methoxyphenyl)propyl]-3-oxo- (CA INDEX NAME)




RN 864162-62-9 CAPLUS  
 CN 2H-1, 4-Benzothiazine-6-carboxylic acid,  
 2-[3-(4-chlorophenyl)propyl]-3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo- (CA INDEX NAME)




RN 864162-63-0 CAPLUS  
 CN 2H-1, 4-Benzothiazine-6-carboxylic acid,  
 2-[3-(4-fluorophenyl)propyl]-3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo- (CA INDEX NAME)




RN 864162-57-2 CAPLUS  
 CN 2H-1, 4-Benzothiazine-6-carboxylic acid,  
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo-2-[3-[4-(trifluoromethoxy)phenyl]propyl]-, ethyl ester (CA INDEX NAME)




RN 864162-58-3 CAPLUS  
 CN 2H-1, 4-Benzothiazine-6-carboxylic acid,  
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo-2-[3-[4-(trifluoromethyl)phenyl]propyl]-, ethyl ester (CA INDEX NAME)




RN 864162-59-4 CAPLUS  
 CN 2H-1, 4-Benzothiazine-6-carboxylic acid,  
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-2-[4-(4-methoxyphenyl)butyl]-3-oxo-, ethyl ester (CA INDEX NAME)




RN 864162-64-1 CAPLUS  
 CN 2H-1, 4-Benzothiazine-6-carboxylic acid,  
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo-2-[3-[4-(trifluoromethoxy)phenyl]propyl]- (CA INDEX NAME)



RN 864162-64-1 CAPLUS  
 CN 2H-1, 4-Benzothiazine-6-carboxylic acid,  
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo-2-[3-[4-(trifluoromethoxy)phenyl]propyl]- (CA INDEX NAME)




RN 864162-65-2 CAPLUS  
 CN 2H-1, 4-Benzothiazine-6-carboxylic acid,  
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo-2-[3-[4-(trifluoromethyl)phenyl]propyl]- (CA INDEX NAME)



RN 864162-66-3 CAPLUS  
 CN 2H-1, 4-Benzothiazine-6-carboxylic acid,  
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-2-[4-(4-methoxyphenyl)butyl]-3-oxo- (CA INDEX NAME)


L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 864162-67-4 CAPLUS  
 CN 2H-1,4-Benzothiazine-6-carboxylic acid,

3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-2-[3-(4-methoxyphenyl)propyl]-3-oxo-, (2S)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 864162-76-5 CAPLUS  
 CN 2H-1,4-Benzothiazine-6-carboxylic acid,

3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-2-[3-(4-methoxyphenyl)propyl]-3-oxo-, ethyl ester, (2R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 864162-91-4 CAPLUS  
 CN 2H-1,4-Benzothiazine-6-carboxylic acid,

3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-2-[3-(4-methoxyphenyl)propyl]-

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2003:532639 CAPLUS  
 DOCUMENT NUMBER: 139:100932  
 TITLE: Preparation of hydroxamic acid derivs. as MMP inhibitors  
 INVENTOR(S): Horiuchi, Yoshihiro  
 PATENT ASSIGNEE(S): Sumitomo Pharmaceuticals Company, Limited, Japan  
 SOURCE: PCT Int. Appl., 93 pp.  
 CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO.  | KIND   | DATE     | APPLICATION NO. | DATE           |          |
|---|--|----------|-----------------|----------------|----------|
| WO 2003055051   | A1   | 20030710 | WO 2002-JP13580 | 20021226       |          |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG |          |                 |                |          |
| CA 2471814  | A1   | 20030710 | CA 2002-2471814 | 20021226       |          |
| AU 2002361096   | A1   | 20030715 | AU 2002-361096  | 20021226       |          |
| EP 1466899  | A1   | 20041013 | EP 2002-792000  | 20021226       |          |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK   | US 20050282905   | A1       | 20051222        | US 2004-500218 | 20040625 |
| US 7540537  | B2   | 20090317 | JP 2001-397638  | A 20011227     |          |
| PRIORITY APPLN. INFO.:  |  |          | WO 2002-JP13580 | W 20021226     |          |

OTHER SOURCE(S): MARPAT 139:100932

GI



AB The title compds. I [R1 and R2 each represents hydrogen, lower alkyl, lower haloalkyl, etc.; X represents methylene or NR3 (R3 represents hydrogen, lower alkyl, etc.); and R4 represents C1-4 alkyl] are prepared. Compds. of this invention in vitro showed IC50 values of < 0.5 nM to 34.4 nM against MMP-13. Formulations are given.

IT 302836-11-9P 302836-18-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

Habte

05/07/2009

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT:


5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)


(User) (prepn. of hydroxamic acid derivs. as MMP inhibitors)

RN 302836-11-9 CAPLUS  
 CN 2H-1,4-Benzothiazine-6-carboxylic acid,  
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-2-[4-[4-(methylsulfonyl)phenoxy]phenyl]methyl]-3-oxo-, ethyl ester (CA INDEX NAME)



RN 302836-18-6 CAPLUS

CN 2H-1,4-Benzothiazine-6-carboxylic acid,  
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-2-[4-[4-(methylsulfonyl)phenoxy]phenyl]methyl]-3-oxo- (CA INDEX NAME)



REFERENCE COUNT:

6


THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2000:756696 CAPLUS  
 DOCUMENT NUMBER: 133:321892  
 TITLE: Preparation of hydroxamic acid derivatives as matrix metallo-proteinase inhibitors  
 INVENTOR(S): Scarlato, Gerard Robert; Hadida Ruah, Sara Sabina; Nishimura, Tamiki; Nakatsuka, Masashi; Samizo, Fumio; Kamikawa, Yumiko; Houtigai, Hitoshi  
 PATENT ASSIGNEE(S): Sumitomo Pharmaceuticals Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 218 pp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

| PATENT NO.   | KIND | DATE     | APPLICATION NO. | DATE       |
|--|------|----------|-----------------|------------|
| WO 2000063197  | A1   | 20001026 | WO 2000-US10383 | 20000419   |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA,<br>ZW |      |          |                 |            |
| RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GM, MR, NE, SN, TD, TG   |      |          |                 |            |
| CA 236994  | A1   | 20001026 | CA 2000-2369947 | 20000419   |
| CA 2369947   | C    | 20080617 |                 |            |
| EP 1173427   | A1   | 20020123 | EP 2000-922291  | 20000419   |
| EP 1173427   | B1   | 20060405 |                 |            |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LI, LV, FI, RO, CR  |      |          |                 |            |
| JP 2002542238  | T    | 20021210 | JP 2000-612289  | 20000419   |
| AT 322487  | T    | 20060415 | AT 2000-922291  | 20000419   |
| ES 2261196   | T3   | 20061116 | ES 2000-922291  | 20000419   |
| US 6713477   | B1   | 20040330 | US 2001-959192  | 20011109   |
| PRIORITY APFLN. INFO.:   |      |          | US 1999-129933P | P 19990419 |
|  |      |          | WO 2000-US10383 | W 20000419 |

OTHER SOURCE(S): MARPAT 133:321892  
 GI

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



AB The title compds. [I], X = (un)substituted alkylene, ortho-heteroarylene; Y1 = O, S, SO, SO2; Y2 = O, S; one of R1 and R3 = (CH2)nCR5R6CONHOH; the other R1 and R3 = H, (un)substituted alkyl, cycloalkyl; R2 = H, (un)substituted alkyl, alkenyl, etc.; R4-R6 = H, (un)substituted alkyl, alkenyl, etc.; or R5 may be joined with R4 or R6 to form with the carbon atom which they attach (un)substituted cycloalkane or heterocycloalkane; n = 0-4], useful as matrix metallo-proteinase (e.g., MMP-2, MMP-3, MMP-9, and MMP-13) inhibitors, were prepared. E.g., a multi-step synthesis of 1,4-benzothiazin-3(4H)-one II which showed IC50 of 1.0  $\mu$ M against MMP-2, and 20% inhibition of TNF- $\alpha$  production at 5  $\mu$ M, was given.

IT RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) [preparation of hydroxamic acid derivs. as matrix metallo-proteinase inhibitors]

RN 302834-55-5 CAPLUS

CN 2H-1,4-Benzothiazine-7-carboxylic acid,

3,4-dihydro-4-[2-(hydroxymino)-2-oxoethyl]-2-[(4-methoxyphenyl)methyl]-3-oxo-, methyl ester (CA INDEX NAME)


L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

IT 302833-93-8 302833-98-3P 302834-00-0P  
 302834-01-1P 302834-02-2P 302834-03-3P  
 302834-06-6P 302834-12-4P 302834-13-5P  
 302834-14-6P 302834-15-7P 302834-16-8P  
 302834-17-9P 302834-54-4P 302834-55-6P  
 302834-57-7P 302834-58-8P 302834-46-7P  
 302836-03-9P 302836-05-1P 302836-08-4P  
 302836-09-5P 302836-10-8P 302836-11-9P  
 302836-12-0P 302836-13-1P 302836-14-2P  
 302836-15-3P 302836-16-4P 302836-17-5P  
 302836-18-6P 302836-19-7P 302836-20-0P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) [preparation of hydroxamic acid derivs. as matrix metallo-proteinase inhibitors]

RN 302833-93-8 CAPLUS

CN 2H-1,4-Benzothiazine-6-carboxylic acid,

3,4-dihydro-4-[2-(hydroxymino)-2-oxoethyl]-3-oxo-2-(phenylmethyl)- (CA INDEX NAME)




RN 302833-98-3 CAPLUS

CN 2H-1,4-Benzothiazine-6-carboxylic acid,


3,4-dihydro-4-[2-(hydroxymino)-2-oxoethyl]-3-oxo-2-(phenylmethyl)- (CA INDEX NAME)

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)




RN 302834-00-0 CAPLUS

CN 2H-1,4-Benzothiazine-6-carboxylic acid,  
 2-[(4-chlorophenoxy)phenyl]methyl-3,4-dihydro-4-[2-(hydroxymino)-2-oxoethyl]-3-oxo- (CA INDEX NAME)



RN 302834-01-1 CAPLUS


CN 2H-1,4-Benzothiazine-6-carboxylic acid,  
 3,4-dihydro-4-[2-(hydroxymino)-2-oxoethyl]-3-oxo-2-(phenylmethyl)-, sodium salt (1:1) (CA INDEX NAME)




● Na

RN 302834-02-2 CAPLUS


CN 2H-1,4-Benzothiazine-6-carboxylic acid,  
 2-[(4-chlorophenoxy)phenyl]methyl-3,4-dihydro-4-[2-(hydroxymino)-2-oxoethyl]-3-oxo- (CA INDEX NAME)



RN 302834-03-3 CAPLUS  
 CN 2H-1,4-Benzothiazine-6-carboxylic acid,  
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo-2-[(4-trifluoromethoxy)phenyl]methyl- (CA INDEX NAME)




RN 302834-06-6 CAPLUS  
 CN 2H-1,4-Benzothiazine-6-carboxylic acid,  
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo-2-(phenylmethyl)-,  
 sodium salt (1:1) (CA INDEX NAME)




● Na


RN 302834-12-4 CAPLUS  
 CN 2H-1,4-Benzothiazine-6-carboxylic acid,  
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-2-[(4-methoxyphenyl)methyl]-3-  
 oxo-, ethyl ester (CA INDEX NAME)




RN 302834-13-5 CAPLUS  
 CN 2H-1,4-Benzothiazine-6-carboxylic acid,  
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo-2-(phenylmethyl)-,  
 ethyl ester (CA INDEX NAME)




RN 302834-14-6 CAPLUS  
 CN 2H-1,4-Benzothiazine-6-carboxylic acid,  
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo-2-(phenylmethyl)-,  
 ethyl ester (CA INDEX NAME)




RN 302834-15-7 CAPLUS  
 CN 2H-1,4-Benzothiazine-6-carboxylic acid,  
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo-2-(4-




RN 302834-16-8 CAPLUS  
 CN 2H-1,4-Benzothiazine-6-carboxylic acid,  
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo-2-[(4-  
 pentyloxy)phenyl]methyl- (CA INDEX NAME)




RN 302834-17-9 CAPLUS  
 CN 2H-1,4-Benzothiazine-6-carboxylic acid,  
 2-[(4-fluorophenyl)methyl]-3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-  
 oxo- (CA INDEX NAME)



RN 302834-54-4 CAPLUS  
 CN 2H-1,4-Benzothiazine-7-carboxylic acid,  
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-2-[(4-methoxyphenyl)methyl]-3-  
 oxo- (CA INDEX NAME)




RN 302834-56-6 CAPLUS  
 CN 2H-1,4-Benzothiazine-7-carboxylic acid,  
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-2-[(4-methoxyphenyl)methyl]-3-  
 oxo-, sodium salt (1:1) (CA INDEX NAME)




● Na


RN 302834-57-7 CAPLUS  
 CN 2H-1,4-Benzothiazine-7-carboxylic acid,  
 2-[(4-chlorophenyl)methyl]-3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-  
 oxo- (CA INDEX NAME)



RN 302834-58-8 CAPLUS  
 CN 2H-1,4-Benzothiazine-7-carboxylic acid,  
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo-2-[(4-  
 phenoxyphenyl)methyl]- (CA INDEX NAME)




RN 302835-46-7 CAPLUS  
 CN 2H-1,4-Benzothiazine-7-carboxylic acid,  
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo-2-(phenylmethyl)- (CA INDEX NAME)




RN 302836-03-9 CAPLUS  
 CN 2H-1,4-Benzothiazine-6-carboxylic acid,  
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo-, ethyl ester (CA INDEX NAME)


3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-2-[(4-hydroxyphenyl)methyl]-3-oxo-, ethyl ester (CA INDEX NAME)




RN 302836-05-1 CAPLUS  
 CN 2H-1,4-Benzothiazine-6-carboxylic acid,  
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo-2-[(4-trifluoromethoxy)phenylmethyl]-, ethyl ester (CA INDEX NAME)




RN 302836-08-4 CAPLUS  
 CN 2H-1,4-Benzothiazine-6-carboxylic acid,  
 2-[(4-(1,3-benzodioxol-5-yloxy)phenyl)methyl]-3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo-, ethyl ester (CA INDEX NAME)




RN 302836-09-5 CAPLUS  
 CN 2H-1,4-Benzothiazine-6-carboxylic acid,  
 2-[(4-(3-fluorophenoxy)phenyl)methyl]-3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo-, ethyl ester (CA INDEX NAME)




RN 302836-10-8 CAPLUS  
 CN 2H-1,4-Benzothiazine-6-carboxylic acid,  
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-2-[(4-(3-methoxyphenoxy)phenyl)methyl]-3-oxo-, ethyl ester (CA INDEX NAME)




RN 302836-11-9 CAPLUS  
 CN 2H-1,4-Benzothiazine-6-carboxylic acid,  
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-2-[(4-(4-methylsulfonyl)phenoxy)phenylmethyl]-3-oxo-, ethyl ester (CA INDEX NAME)




RN 302836-12-0 CAPLUS  
 CN 2H-1,4-Benzothiazine-6-carboxylic acid,  
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo-2-[(4-(4-pyridinyl)oxy)phenylmethyl]- (CA INDEX NAME)




RN 302836-13-1 CAPLUS  
 CN 2H-1,4-Benzothiazine-6-carboxylic acid,  
 2-[(4-(1,3-benzodioxol-5-yloxy)phenyl)methyl]-3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo- (CA INDEX NAME)




RN 302836-14-2 CAPLUS  
 CN 2H-1,4-Benzothiazine-6-carboxylic acid,  
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo-2-[(4-(3-trifluoromethyl)phenoxy)phenylmethyl]- (CA INDEX NAME)



RN 302836-15-3 CAPLUS  
 CN 2H-1,4-Benzothiazine-6-carboxylic acid,  
 2-[(4-(3-fluorophenoxy)phenyl)methyl]-3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-oxo- (CA INDEX NAME)




RN 302836-16-4 CAPLUS  
 CN 2H-1,4-Benzothiazine-6-carboxylic acid,  
 3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-2-[(4-(4-methoxyphenyl)sulfonyl)phenylmethyl]-3-oxo- (CA INDEX NAME)




L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)


RN 302836-17-5 CAPLUS  
CN 2H-1,4-Benzothiazine-6-carboxylic acid,  
3,4-dihydro-4-[2-(hydroxymino)-2-oxoethyl]-2-[(4-(3-methoxyphenoxy)phenyl)methyl]-3-oxo- (CA INDEX NAME)



RN 302836-18-6 CAPLUS  
CN 2H-1,4-Benzothiazine-6-carboxylic acid,  
3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-2-[[4-[4-  
(methylsulfonyl)phenoxy]phenyl]methyl]-3-oxo- (CA INDEX NAME)




RN 302836-19-7 CAPLUS  
CN 2H-1,4-Benzothiazine-7-carboxylic acid,  
2-[(4-chlorophenyl)methyl]-3,4-dihydro-4-[2-(hydroxyamino)-2-oxoethyl]-3-  
oxo-, ethyl ester (CA INDEX NAME)



RN 302836-20-0 CAPLUS

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)  
CN 2H-1,4-Benzothiazine-7-carboxylic acid,  
3,4-dihydro-4-[2-(hydroxymino)-2-oxoethyl]-3-oxo-2-[(4-  
phenoxyphenyl)methyl]-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

25/07/2020